You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
The startup aims to develop a low-cost, high-throughput proteomics platform that combines biochemistry with computer science and information technology.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The UK-based firm anticipates that it will have a high sensitivity test available in a few months that can detect active infections.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.